Watson Pharma, Endo settle pain drug patent suit. Targacept's ADHD drug fails mid-stage trial, shares fall. Print E-mail
By Mary Davila   
Thursday, 07 October 2010 18:34
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 07, 2010.

Watson Pharma, Endo settle pain drug patent suit: Watson says gets royalty-free US license to drug.  Says can launch generic drug by Sept. 15, 2012. Watson Pharmaceuticals (WPI.N) settled a patent dispute with Endo Pharmaceuticals Inc (ENDP.O), Endo's fourth this year in a series of settlements over its pain drug, giving Watson the right to launch a generic version in September 2012.
The settlement grants Watson, one of the largest U.S. generic drugmakers, the right to market a copycat version of the drug Opana in the United States without any royalty payments, Watson said in a statement. Other details of the settlement were not disclosed.

Targacept's ADHD drug fails mid-stage trial, shares fall
- Sees AstraZeneca ending ADHD drug development.  Shares down as much as 6%.
Targacept (TRGT.O) said its experimental drug to treat attention deficit hyperactivity disorder (ADHD) in adults failed to meet the main goal of a mid-stage trial, sending its shares down as much as 6 percent. Targacept, which had licensed the drug AZD1446 to AstraZeneca (AZN.L) in 2005, said the drug did not improve ADHD symptoms as compared to a dummy pill. Targacept said it does not expect AstraZeneca to progress AZD1446 as a treatment for ADHD. AstraZeneca is expected to give an update on future development of AZD1446 in treatment of Alzheimer's in the coming months, Targacept said.
The study was one of several studies designed by AstraZeneca to assess efficacy in potential later-stage development of AZD1446 in either or both of Alzheimer's disease and ADHD, Targacept said. In addition to the ADHD trial, the company is testing the drug in three other clinical studies to test efficacy in Alzheimer's disease. Targacept shares, which have lost 3 percent since they reported quarterly results in August, were down over 2 percent at $22.41 early Thursday morning on Nasdaq. 
Also Thursday:

AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced that Mr. Mark Tauscher has been appointed to the Company's Board of Directors, effective October 5, 2010.
Akorn, Inc. (Nasdaq:AKRX) will host a conference call on Tuesday, November 9, 2010, to discuss third quarter 2010 results followed by a Q&A session.  

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN)
, today announced that the Company will report its financial results for the third quarter ended September 30, 2010 on Thursday, October 21, 2010 before the financial markets open.

ARCA biopharma, Inc. (Nasdaq: ABIO)
, a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that the European Patent Office has issued a patent on methods of treating heart failure patients with bucindolol based on genetic targeting.

AtheroNova Inc. (OTCBB: AHRO)
("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that the Company's initial preclinical animal study conducted at a major university demonstrating the study group having a 95% less occurrence of arterial plaque compared to the control group was reported in the Preclinical Results section of the October 4, 2010 edition of "BioCentury Part II, Essential Surveillance for Biotech and Pharma.

BioClinica™, Inc., (NASDAQ: BIOC)
, a leading provider of clinical trial management services, today announced that it has signed a three-year, multi-million dollar agreement for enterprise-wide EDC technology and data management services with a global, multi-billion dollar division of a Top 10 pharmaceutical company. Designed for maximum efficiency and flexibility,BioClinica Express™ will support nearly 200 studies annually for this organization.

BioDelivery Sciences International, Inc. (Nasdaq: BDSI)
announced a license and supply agreement with TTY Biopharm Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of China, Taiwan.

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN)
today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28, at 5:00 p.m. ET to discuss third quarter 2010 financial results.

Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD)
today announced in its new monthly President's Column, posted at www.biomoda.com, that it is extending the pilot clinical trial of its CyPath® diagnostic assay for the detection of early-stage lung cancer to recruit additional participants for the positive control group, patients who have been diagnosed with lung cancer but have not yet begun treatment for the disease.

China Cord Blood Corporation ("CCBC" or "the Company") (NYSE:CO)
, the first and largest cord blood bank operator in China, today announced that since the authorization of the stock repurchase program on September 15, 2010, the Company has repurchased approximately 309,000 ordinary shares for approximately US$1.6 million through October 6, 2010 at an average price per share of US$5.32.

BSD Medical Corp. (NASDAQ: BSDM)
today reported that a study titled "Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments"- has been published in Current Medicinal Chemistry (Current Medicinal Chemistry, 2010, 17, 3045-3057).

Codexis, Inc. (Nasdaq:CDXS)
today announced the company will host a conference call and webcast on Thursday, October 28, 2010 at 4:30 p.m. Eastern Time to discuss its third quarter financial results for the period ended September 30, 2010.  

CVS Caremark (NYSE:CVS)
announced today that it has appointed Jonathan C. Roberts as Chief Operating Officer of its pharmacy benefit management business. 

Dendreon Corporation (Nasdaq:DNDN)
today announced that management will host a conference call on Wednesday, November 3, 2010 at 4:30 p.m. ET to review third quarter financial results.  

Depomed, Inc. (NASDAQ: DEPO)
today announced presentations of clinical data of Breeze 1 and 2 at the North American Menopause Society (NAMS) Annual Meeting in Chicago, Illinois on October 8, 2010.

FACT Corporation (OTCBB: FCTOA)
today announced theretail launch of its new line of all natural, high fiber, Nutrition First™ bake mixes at Texas based H-E-B supermarkets.H-E-B has grown from a small, family-owned store in Kerrville, Texas to more than 300 stores across Texas and Mexico.

Halozyme Therapeutics, Inc. (Nasdaq:HALO)
, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 14, 2010 in New York.

Hospira (NYSE:HSP)
, a leading global specialty pharmaceutical and medication delivery company, today announced that the new national infusion pump and solutions and equipment agreements with Novation became effective Oct. 1, 2010.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC)
, a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that Manish Singh, Ph.D., the company’s President and CEO, will present during the PrecisionIR Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference.

International Stem Cell Corporation (OTCBB:ISCO)
, www.internationalstemcell.com, will present data on its progress toward producing human liver cells from immune-matched patient-specific parthenogenetic stem cells at The Liver Meeting®, the 61st Annual Meeting of the American Association for the Study of Liver Diseases (ASSLD), in Boston, MA from October 29 - November 2, 2010.

IsoRay, Inc. (Amex:ISR)
announced today another milestone in the use of Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy). Doctors at a world renowned medical facility have performed the world's first Cs-131 brachytherapy seed implant following a wedge resection of a lung tumor which originated from a form of malignant uterine cancer.

International Stem Cell Corporation (OTCBB:ISCO)
, www.internationalstemcell.com, will present data on its progress toward producing human liver cells from immune-matched patient-specific parthenogenetic stem cells at The Liver Meeting®, the 61st Annual Meeting of the American Association for the Study of Liver Diseases (ASSLD), in Boston, MA from October 29 - November 2, 2010.

Kraig Biocraft Laboratories, Inc. (PINKSHEETS:KBLB)
announces today that its ticker has changed to KBLB.PK.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
today announced that it has agreed to divest and sell its combinatorial chemical library and associated proprietary technology to Venenum Biodesign, LLC, an affiliate of Medical Diagnostic Laboratories, LLC, members of Genesis Biotechnology Group (GBG), for $1.8 million.

Medidata Solutions (NASDAQ: MDSO)
, a leading global provider of SaaS-based clinical development solutions, today announced that members of its management team will deliver the following presentations at key events in October: “Practical Experiences Transferring Data from EDC to Data Warehouses”

NuPathe Inc. (NASDAQ: PATH)
a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces the appointment of Michael Marino as Vice President, General Counsel and Corporate Secretary.

NuVim, Inc. (PINKSHEETS:NUVM)
, today announced agreement with Equiti-trend Advisors, LLC to represent NuVim, Inc. in its investor awareness and shareholder relations activities.A San Diego-based agency, Equiti-trend provides a suite of custom services for public companies seeking both short and long term results in investor awareness programs.

Pfizer Inc. (NYSE:PFE)
today announced that data from a Phase 2 efficacy and safety study of tasocitinib (proposed INN name for CP-690,550), the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.

Redpoint Bio Corporation (OTC Bulletin Board:RPBC)
, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, announced that it has advanced its discovery program for all-natural enhancers of salty taste.  

Savanna East Africa, Inc. (PINKSHEETS:NVAE) (OTCQB: NVAE)
has scheduled a Webcast for tomorrow, October 8th to present a preview of the Company's anticipated activity and events for the 4th calendar quarter of 2010 and to provide an update on the Company's acquisition opportunities.

Spherix Incorporated (Nasdaq:SPEX)
, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant (p<0.05) reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes (U.S. ITT LOCF, n=101 and Global PP, n=92)*.

Spherix Incorporated (Nasdaq:SPEX)
, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has entered into agreements to sell $5.25 million of shares of its Series B Convertible Preferred Stock and warrants to purchase shares of its common stock in a registered offering to institutional investors. 

Star Scientific, Inc. (Nasdaq:  CIGX)
has issued the following comment by Paul L. Perito, Rock Creek Pharmaceuticals' Chairman and CEO:  "We are gratified that the Roskamp Institute, a highly credentialed scientific foundation, has made a significant medical discovery that we believe holds the potential for creating a therapy that could play a role in alleviating the scourge of Alzheimer's Disease.  

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) and Abbott (NYSE:ABT)
today announced that Sucampo Pharma Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc., has submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market Amitiza® (lubiprostone) 24 mcg for the treatment of chronic idiopathic constipation (CIC).

Targacept, Inc. (NASDAQ: TRGT)
today announced top-line results from a Phase 2 clinical trial of AZD1446 conducted by AstraZeneca in adults with attention deficit/hyperactivity disorder (ADHD).

Theravance, Inc. (NASDAQ:THRX)
announced today that it will release financial results for the period ended September 30, 2010 after market close on Thursday, October 21, 2010.

Watson Pharmaceuticals, Inc. (NYSE:WPI)
today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Endo Pharmaceuticals, Inc. on outstanding patent litigation related to Endo's Opana® ER (Oxymorphone ER) product.  



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter